Internal Medicine, Endocrinology, Diabetes, & Metabolism · Baton Rouge, LA
NPI
1194935635
Since 2007
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
7373 Perkins Rd
Baton Rouge, LA, 70808
Phone (225) 769-4044
Groups this clinician bills Medicare through
Medicare paid, 2024
$195K
10,729 services
Medicare patients, 2024
534
Average age 73
Drug cost, 2024
$2.5M
9,102 prescriptions
Company payments, 2025
$531
From 9 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jonathan G Welden was code J0897 (injection, denosumab, 1 mg), 1,500 times for 17 patients. In total Jonathan G Welden billed 10,729 services in 64 codes, and Medicare paid $195K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-08-16.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 1,500 | 17 | $20.61 | $31K |
| 36415 Venipuncture Blood Collection | Office | 793 | 420 | $8.63 | $6,843 |
| 99214 Office E&M - Established | Office | 783 | 405 | $79.73 | $62K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 763 | 416 | $11.14 | $8,498 |
| 84443 Clinical Chemistry | Office | 745 | 403 | $16.42 | $12K |
| 84439 Clinical Chemistry | Office | 738 | 399 | $8.83 | $6,513 |
| 80053 Clinical Chemistry | Office | 525 | 289 | $10.32 | $5,419 |
| 80061 Clinical Chemistry | Office | 509 | 280 | $13.09 | $6,661 |
| 83036 Blood Count | Office | 355 | 182 | $9.50 | $3,373 |
| 99213 Office E&M - Established | Office | 115 | 89 | $56.66 | $6,516 |
| 82570 Clinical Chemistry | Office | 115 | 109 | $5.05 | $581 |
| 82043 Clinical Chemistry | Office | 112 | 106 | $5.63 | $630 |
| 82306 Clinical Chemistry | Office | 99 | 73 | $29.01 | $2,872 |
| 80048 Clinical Chemistry | Office | 72 | 61 | $8.29 | $597 |
| 96372 Injection Administration | Office | 66 | 23 | $10.12 | $668 |
By year: 2022 $166K for 14,261 services; 2023 $165K for 8,028 services; 2024 $195K for 10,729 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 793 | 420 | $8.63 | $6,843 |
| 84443 Clinical Chemistry | 745 | 403 | $16.42 | $12K |
| 84439 Clinical Chemistry | 738 | 399 | $8.83 | $6,513 |
| 80053 Clinical Chemistry | 525 | 289 | $10.32 | $5,419 |
| 80061 Clinical Chemistry | 509 | 280 | $13.09 | $6,661 |
| 83036 Blood Count | 355 | 182 | $9.50 | $3,373 |
| 82570 Clinical Chemistry | 115 | 109 | $5.05 | $581 |
| 82043 Clinical Chemistry | 112 | 106 | $5.63 | $630 |
| 82306 Clinical Chemistry | 99 | 73 | $29.01 | $2,872 |
| 80048 Clinical Chemistry | 72 | 61 | $8.29 | $597 |
Medicare prescription drug claims, 2024
In 2024, the drug Jonathan G Welden prescribed most often to Medicare patients was Levothyroxine Sodium, with 1,822 prescriptions and refills. In total Jonathan G Welden wrote 9,102 Medicare prescriptions that cost $2.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 1,822 | 4,216 | 422 | $16K |
| Synthroid Levothyroxine Sodium | 970 | 1,802 | 175 | $72K |
| Ozempic Semaglutide | 451 | 682 | 86 | $634K |
| Jardiance Empagliflozin | 417 | 612 | 76 | $345K |
| Metformin Hcl Generic | 370 | 935 | 99 | $2,786 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 279 | 513 | 69 | $41K |
| Glimepiride Generic | 278 | 644 | 63 | $1,789 |
| Atorvastatin Calcium Generic | 236 | 631 | 68 | $2,582 |
| Metformin Hcl Er Metformin Hcl | 226 | 566 | 68 | $1,879 |
| Mounjaro Tirzepatide | 221 | 254 | 37 | $261K |
| Testosterone Cypionate Generic | 175 | 278 | 38 | $6,866 |
| Simvastatin Generic | 168 | 464 | 47 | $1,425 |
| Novolog Flexpen Insulin Aspart | 131 | 223 | 42 | $37K |
| Januvia Sitagliptin Phosphate | 118 | 201 | 21 | $108K |
| Pravastatin Sodium Generic | 110 | 271 | 30 | $1,193 |
Brand drugs: 4,349 claims; generic drugs: 4,379 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jonathan G Welden $531 ($531 in general payments such as food, travel and fees) from 9 companies. The largest payer was Sequel Med Tech, LLC with $154.
| Company | Payments | Amount |
|---|---|---|
| Sequel Med Tech, LLC | 2 | $154 |
| Ascendis Pharma Endocrinology Inc ASND | 1 | $119 |
| Novo Nordisk Inc NVO | 1 | $90.31 |
| Ascensia Diabetes Care Us Inc. | 1 | $43.51 |
| Beta Bionics, Inc. BBNX | 3 | $37.3 |
| Abbvie Inc. ABBV | 1 | $25.31 |
| Neurocrine BioSciences, Inc. NBIX | 1 | $24.04 |
| Dexcom, Inc. DXCM | 1 | $20.34 |
| Xeris Pharmaceuticals, Inc. | 1 | $17.67 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.